Grandfield & Dodd, LLC
- SEC CIK
- 0001308016
- Latest filing
- Aug 7, 2026
NKTR holding history
Nektar Therapeutics in every 13F filed by Grandfield & Dodd, LLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NKTR overviewAll 13F holders of NKTRFull Q2 2026 holdings
- Shares (Q4 2022)
- 0
- Sold out in Q4 2022
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 7
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2022 | 0 | $0 | 0.0% | −25,061−100.0% | Sold out | Holders |
| Q3 2022 | 25,061 | $80.0K | <0.1% | −8,749−25.9% | Reduced | Holders |
| Q2 2022 | 33,810 | $130.0K | <0.1% | −10,133−23.1% | Reduced | Holders |
| Q1 2022 | 43,943 | $240.0K | <0.1% | +3,350+8.3% | Added | Holders |
| Q4 2021 | 40,593 | $550.0K | <0.1% | +10,670+35.7% | Added | Holders |
| Q3 2021 | 29,923 | $540.0K | <0.1% | +1,865+6.6% | Added | Holders |
| Q2 2021 | 28,058 | $480.0K | <0.1% | +850+3.1% | Added | Holders |
| Q1 2021 | 27,208 | $540.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.